The 10 Most Influential Businesswomen to Follow in 2020

Catherin
e
Pearc
Helping to Bring Promising Medicines Forward
She is atalented drug-development professional, an
impeccable leader, and marketing expert. Meet
Catherine Pearce, DHSc, MBAChief Operating
Officer at CinRx, whose firm determination and passion
helped her in achieve many career milestones in the
pharmaceutical industry.
She has more than 20 years of experience in
pharmaceutical clinical development, business
development, and R&D at companies including Merck,
Ethicon and Medpace. Most recently, she served as the
Vice President of Research and Development for New
Therapeutic Entities (NTEs) at Teva, where she was
responsible for developing over 20 repurposed products
across multiple therapeutic areas.
Catherine has co-founded and assembled CinRx’s
talented leadership team that has submitted multiple New
Drug Applications (NDAs) throughout their careers,
overseen hundreds of Investigational New Drug (INDs)
applications, as well as Clinical Trial Applications
(CTAs), and Investigational Medicinal Product Dossiers
(IMPDs). Between the approximately 15 person team,
the group has published 36 patents and participated in
more than 2300 clinical trials which resulted in 50
approved therapeutics worldwide.
Into the Shoes of Catherine Pearce
Catherine started her career in sales and marketing with
Hoffman-LaRoche in 1997 and later with Merck, where
she launched cardiovascular products in hypertension
and lipid management. For 5 years, she served as
aClinical Project Director for Phase I-III global studies at
a CRO, Medpace, in a variety of therapeutic areas,
including cardiovascular, diabetes, nephrology and
neuropathic pain studies. She later started the Business
Development group in 2007, and subsequently left the
company in 2011 to pursue opportunities in life science
investment and device development at Ethicon (J&J).
In 2012, she joined Teva as Vice President, R&D, to lead
the medical assessments for the newly created New
Therapeutic Entities (NTE) team, a group responsible for
building a portfolio of drugs through repurposing generic
molecules. After successfully helping to add over 22
repurposed molecules to Teva’s R&D portfolio, she left
to co-found CinRx Pharma, LLC—a privately held
biotech company dedicated to drug development. Being
a Chief Operating Officer at CinRx, her daily
responsibilities include the overall management of the
company and its operations, business development,
strategic direction and planning, for CinRx and its
subsidiary organizations.
10 | JUNE 2020 www.insightssuccess.com